Anti-inflammatory medicaments

1 . An adduct comprising a molecule binding with a kinase, said molecule having the formula

Wherein:

R 1 is selected from the group consisting of aryls and heteroaryls;

each X and Y is individually selected from the group consisting of —O—, —S—, —NR 6 —, —NR 6 SO 2 —, —NR 6 CO—, alkynyls, alkenyls, alkylenes, —O(CH 2 ) h —, and —NR 6 (CH 2 ) h —, where each h is individually selected from the group consisting of 1, 2, 3, or 4, and where for each of alkylenes, —O(CH 2 ) h —, and —NR 6 (CH 2 ) h —, one of the methylene groups present therein may be optionally double-bonded to a side-chain oxo group except that where —O(CH 2 ) h — the introduction of the side-chain oxo group does not form an ester moiety;

A is selected from the group consisting of aromatic, monocycloheterocyclic, and bicycloheterocyclic rings;

D is phenyl or a five- or six-membered heterocyclic ring selected from the group consisting of pyrazolyl, pyrrolyl, imidazolyl, oxazolyl, thiazolyl, furyl, pyridyl, and pyrimidyl;

E is selected from the group consisting of phenyl, pyridinyl, and pyrimidinyl;

L is selected from the group consisting of —C(O)— and —S(O) 2 —;

j is 0 or 1;

m is 0 or 1;

n is 0 or 1;

p is 0 or 1;

q is 0 or 1;

t is 0 or 1;

Q is selected from the group consisting of

each R 4 group is individually selected from the group consisting of —H, alkyls, aminoalkyls, alkoxyalkyls, aryls, aralkyls, heterocyclyls, and heterocyclylalkyls except when the R 4 substituent places a heteroatom on an alpha-carbon directly attached to a ring nitrogen on Q;

when two R 4 groups are bonded with the same atom, the two R 4 groups optionally form an alicyclic or heterocyclic 4-7 membered ring;

each R 5 is individually selected from the group consisting of —H, alkyls, aryls, heterocyclyls, alkylaminos, arylaminos, cycloalkylaminos, heterocyclylaminos, hydroxys, alkoxys, aryloxys, alkylthios, arylthios, cyanos, halogens, perfluoroalkyls, alkylcarbonyls, and nitros;

each R 6 is individually selected from the group consisting of —H, alkyls, allyls, and β-trimethylsilylethyl;

each R 8 is individually selected from the group consisting of alkyls, aralkyls, heterocyclyls, and heterocyclylalkyls;

each R 9 group is individually selected from the group consisting of —H, —F, and alkyls, wherein when two R 9 groups are geminal alkyl groups, said geminal alkyl groups may be cyclized to form a 3-6 membered ring;

each Z is individually selected from the group consisting of —O— and —N(R 4 )—; and

each ring of formula (III) optionally includes one or more of R 7 , where R 7 is a noninterfering substituent individually selected from the group consisting of —H, alkyls, aryls, heterocyclyls, alkylaminos, arylaminos, cycloalkylaminos, heterocyclylaminos, hydroxys, alkoxys, aryloxys, alkylthios, arthylthios, cyanos, halogens, nitrilos, nitros, alkylsulfinyls, alkylsulfonyls, aminosulfonyls, and perfluoroalkyls.

2 . The adduct of claim 1 , said molecule binding at the region of a switch control pocket of said kinase.

3 . The adduct of claim 2 , said switch control pocket of said kinase comprising an 30 amino acid residue sequence operable for binding to said Formula (III) molecule.

4 . The adduct of claim 2 , said switch control pocket selected from the group consisting of simple, composite and combined switch control pockets.

5 . The adduct of claim 4 , said region being selected from the group consisting of the a-C helix, a-D helix, the catalytic loop, the switch control ligand sequence, and the C-terminal residues and combinations thereof.

6 . The adduct of claim 5 , said a-C helix including SEQ ID NO.2.

7 . The adduct of claim 5 , said catalytic loop including SEQ ID NO.3.

8 . The adduct of claim 5 , said switch control ligand sequence being selected from the group consisting of SEQ ID NO.5, SEQ ID NO.6, and combinations thereof.

9 . The adduct of claim 5 , said C-lobe residues including WI97, MI98, HI99, Y200.

10 . The adduct of claim 1 , said kinase selected from the group consisting of the consensus wild type sequence and disease polymorphs thereof.

11 . The adduct of claim 1 said molecule having the structure of the compound of claim 1.